Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 9/20 | 0.52 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.42 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.42 |
| ▸ | TYR | P14679 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12813947 | 0.87 | ERN1 (0.50) | ERN1TRIM24TRIM33TYR | |
| SCHEMBL31114205 | 0.87 | ERN1 (0.50) | ERN1TRIM24TRIM33TYR | |
| SCHEMBL5296637 | 0.84 | ERN1 (0.44) | ERN1TRIM24TRIM33TYR | |
| SCHEMBL692164 | 0.84 | ERN1 (0.48) | ERN1TRIM24TRIM33TYR | |
| SCHEMBL31183326 | 0.84 | ERN1 (0.48) | ERN1TRIM24TRIM33TYR | |
| SCHEMBL874654 | 0.84 | ERN1 (0.48) | ERN1TRIM24TRIM33TYR | |
| SCHEMBL31183331 | 0.84 | ERN1 (0.48) | ERN1TRIM24TRIM33TYR | |
| SCHEMBL4289408 | 0.83 | ERN1 (0.54) | ERN1TRIM24TRIM33TYR | |
| SCHEMBL415162 | 0.82 | ERN1 (0.50) | ERN1TRIM24TRIM33 | |
| SCHEMBL1464801 | 0.82 | ERN1 (0.50) | ERN1TRIM24TRIM33 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116177489-A | Method for producing hydrogen by catalyzing methanol | 武汉绿知行环保科技有限公司 | 2023-05-30 | — | — | CN | claimed |
| EP-4619097-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF | Samsara Therapeutics Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-12415771-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2025-09-16 | — | — | US | disclosed |
| EP-4171563-B1 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025106477-A1 | NOVEL AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF | Samsara Therapeutics Inc. (US) | 2025-05-22 | — | — | WO | disclosed |
| US-20250092019-A1 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2025-03-20 | — | — | US | disclosed |
| CN-114008012-B | Compounds for the treatment of neuromuscular disorders | NMD制药股份公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-119390705-A | 5-Oxa-2-azaspiro [3.4] octane derivatives as M4 agonists | 诺华股份有限公司 | 2025-02-07 | — | — | CN | disclosed |
| EP-4228755-B1 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2024-12-11 | — | — | EP | disclosed |
| EP-4171571-B1 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2024-10-30 | — | — | EP | disclosed |
| US-7834023-B2 | Substituted dihydroquinazolines as platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-20090275538-A1 | ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS | UNIVERSITE LAVAL (CA) | 2009-11-05 | — | — | US | disclosed |
| WO-2009097695-A1 | ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS | CHLORION PHARMA, INC. (CA) | 2009-08-13 | — | — | WO | disclosed |
| EP-2079747-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANABOLIC AGENTS FOR LIVESTOCK ANIMALS | Pfizer Limited (GB) | 2009-07-22 | — | — | EP | disclosed |
| US-20080161288-A1 | COMPOUNDS | PFIZER INC. | 2008-07-03 | — | — | US | disclosed |
| WO-2008044127-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANABOLIC AGENTS FOR LIVESTOCK ANIMALS | PFIZER LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| EP-0906301-B1 | BENZOFURYL DERIVATIVES AND THEIR USE | HOFFMANN LA ROCHE (CH) | 2002-10-02 | — | — | EP | disclosed |
| US-5955495-A | BENZOFURAN-2-CARBOXAMIDINE OR 2-CARBOXAMIDOXIME COMPOUNDS USEFUL IN THE CONTROL OR PREVENTION OF ILLNESSES OR DISORDERS OF THE CENTRAL NERVOUS SYSTEM SUCH AS MIGRAINE, SCHIZOPHRENIA, ANXIETY STATES, SLEEP DISORDERS, ANOREXIA, ALZHEIMER'S | HOFFMANN-LA ROCHE INC. (US) | 1999-09-21 | — | — | US | disclosed |
| EP-0906301-A1 | BENZOFURYL DERIVATIVES AND THEIR USE | F. HOFFMANN-LA ROCHE AG (CH) | 1999-04-07 | — | — | EP | disclosed |
| WO-1997042183-A1 | BENZOFURYL DERIVATIVES AND THEIR USE | F. HOFFMANN-LA ROCHE AG (CH) | 1997-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275538-A1 | ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS | OPRL1, OPRK1, AHR | ERN1 3987/4885TRIM24 717/4885TRIM33 1746/4885 |
| US-20250092019-A1 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | TRPA1, TRPV1, TRPV5 | ERN1 3539/4885TRIM24 3913/4885TRIM33 4130/4885 |
| US-20080161288-A1 | COMPOUNDS | ADRB2, ADRB1, ADRA2C | ERN1 3574/4885TRIM24 3018/4885TRIM33 3105/4885 |
| US-12415771-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, SMN1; SMN2 | ERN1 2210/4885TRIM24 919/4885TRIM33 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.